Two doses of BNT162b2 vaccine are associated with high short-term protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which wanes after six months, while immunity remains high for those with infection-acquired immunity boosted with vaccination, according to a study published online Feb. 16 in the New England Journal of Medicine.
Vaccination ups infection-acquired immunity against SARS-CoV-2
Two doses of BNT162b2 vaccine are associated with high short-term protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which wanes after six months, while immunity remains high for those with infection-acquired immunity boosted with vaccination, according to a study published online Feb. 16 in the New England Journal of Medicine.